BioSpace News Archive

Instem Company NOTOCORD Secures Portion of €4m Grant as Member of Exclusive Scientific Consortium Helping to Make Medications Safer

The FDA is committed to making sure that health care professionals and patients have up-to-date, accurate and actionable information about prescription medications so that informed treatment decisions can be made.

Economic activity in the manufacturing sector expanded in June, and the overall economy grew for the 122nd consecutive month, say the nation’s supply executives in the latest Manufacturing ISM® Report On Business®.

Brooks Automation, Inc. (Nasdaq:BRKS), a leader in automation solutions for the semiconductor manufacturing and life sciences industries, announced today that it has completed the previously announced sale of the company’s Semiconductor Cryogenics business to Edwards Vacuum LLC ( a member of the Atlas Copco Group) for $675 million in cash, subject to adjustments for working capital and other items.

Early clinical development program for achondroplasia augments Pfizer’s Rare Disease portfolio

The Childhood Arthritis and Rheumatology Research Alliance (CARRA) and Lupus Foundation of America (LFA) conducted a first-of-its-kind, multidisciplinary research effort on childhood-onset lupus to assess research priorities for addressing this life-threatening disease.

Minnesota Valley Surgery Center, a NueHealth facility, recently became the first ambulatory surgery center (ASC) in the state of Minnesota to receive the Accreditation Association for Ambulatory Health Care (AAAHC)'s Orthopaedic Advanced Certification, Total Joints Program.

“I’m an amputee with a prosthetic device and thought it was unattractive and bland,” said an inventor, from El Cajon, Calif. “This inspired me to develop a means to apply eye-catching sleeves/covers with unlimited designs for personal expression.”

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the publication of a manuscript describing the activity of allele-selective zinc finger protein transcription-factors (ZFP-TFs) in preclinical models of Huntington’s disease (HD).

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the successful completion of Oxurion’s Phase I clinical trial evaluating the safety and tolerability of a single intravitreal injection of THR-149, a novel Bicycle-based plasma kallikrein (PKal) inhibitor